All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule

TINAGL1 Antibody, FITC conjugated

Datasheet
Code CSB-PA875630LC01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) TINAGL1 Polyclonal antibody
Uniprot No.
Q9GZM7
Target Names
TINAGL1
Alternative Names
TINAGL1 antibody; GIS5 antibody; LCN7 antibody; OLRG2 antibody; TINAGL antibody; PP6614 antibody; PSEC0088 antibody; UNQ204/PRO230 antibody; Tubulointerstitial nephritis antigen-like antibody; Glucocorticoid-inducible protein 5 antibody; Oxidized LDL-responsive gene 2 protein antibody; OLRG-2 antibody; Tubulointerstitial nephritis antigen-related protein antibody; TIN Ag-related protein antibody; TIN-Ag-RP antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Tubulointerstitial nephritis antigen-like protein (250-467AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
FITC
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Related Products

TINAGL1 antibodies

TINAGL1 Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May be implicated in the adrenocortical zonation and in mechanisms for repressing the CYP11B1 gene expression in adrenocortical cells. This is a non catalytic peptidase C1 family protein.
Gene References into Functions
  1. Double immunofluorescence analysis showed that CTLA-2alpha was co-localized with cathepsin L, cathepsin C, and TINAGL1 in placenta. PMID: 25514977
  2. TINAGL1 and B3GALNT1 are possible candidates for drug compounds that inhibit their gene expression PMID: 25521548
Subcellular Location
Secreted.
Protein Families
Peptidase C1 family
Tissue Specificity
Highly expressed in aorta, heart, placenta, kidney and a colorectal adenocarcinoma cell line. Moderately expressed in skeletal muscle, pancreas, lung, lymph nodes, adrenal gland, bone marrow and thyroid. Weakly expressed in colon, small intestine, ovary,
Database Links

HGNC: 19168

OMIM: 616064

KEGG: hsa:64129

STRING: 9606.ENSP00000271064

UniGene: Hs.199368

Promotions
Obtain Rewards by Referring A Friend
Reward For Reviews
Transmembrane Protein Questionnaire with Gifts
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*